2 news items
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
CDTX
15 May 24
it is indicative of the significant potential of CD388 as a universal preventative of seasonal and pandemic influenza. We believe that CD388 may have significant
Cidara Therapeutics Reacquires Global Development And Commercial Rights To CD388 From Johnson & Johnson For A One Time Payment Of $85M; Announces Private Placement Financing Of $240M
CDTX
JNJ
24 Apr 24
preventative against seasonal and pandemic influenza A and B, beginning with a Phase 2b clinical trial in the upcoming Northern Hemisphere influenza season
- Prev
- 1
- Next